

Richard Sposto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3702346/publications.pdf>

Version: 2024-02-01

48
papers

1,421
citations

361045

20
h-index

344852

36
g-index

49
all docs

49
docs citations

49
times ranked

2953
citing authors

#	ARTICLE	IF	CITATIONS
1	Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). <i>Haematologica</i> , 2022, 107, 2295-2303.	1.7	8
2	Independent Assessment of the Children's Hepatic Tumors International Collaboration Risk Stratification for Hepatoblastoma and the Association of Tumor Histological Characteristics With Prognosis. <i>JAMA Network Open</i> , 2022, 5, e2148013.	2.8	7
3	Surveillance for radiation-related late effects in childhood cancer survivors: The impact of using volumetric dosimetry. <i>Cancer Medicine</i> , 2021, 10, 905-913.	1.3	3
4	Mental stress causes vasoconstriction in subjects with sickle cell disease and in normal controls. <i>Haematologica</i> , 2020, 105, 83-90.	1.7	40
5	mRNA and miRNA Profiles of Exosomes from Cultured Tumor Cells Reveal Biomarkers Specific for HPV16-Positive and HPV16-Negative Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8570.	1.8	16
6	Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. <i>Clinical Cancer Research</i> , 2020, 26, 2297-2307.	3.2	28
7	Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2473-2478.	3.3	26
8	Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method. <i>Pharmaceutical Statistics</i> , 2019, 18, 659-670.	0.7	2
9	Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial. <i>Clinical Trials</i> , 2019, 16, 599-609.	0.7	1
10	Rejoinder. <i>Clinical Trials</i> , 2019, 16, 613-615.	0.7	0
11	Clinical findings and outcomes of MRI staging of breast cancer in a diverse population. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 315-324.	1.1	3
12	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2019, 33, 884-892.	3.3	158
13	Dose Sculpting Intensity Modulated Radiation Therapy for Vertebral Body Sparing in Children With Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 550-557.	0.4	9
14	Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. <i>Leukemia</i> , 2018, 32, 2316-2325.	3.3	88
15	Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. <i>Cell Reports</i> , 2018, 25, 2177-2191.e7.	2.9	92
16	Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the "head-start" and II clinical trials. <i>Journal of Neuro-Oncology</i> , 2018, 140, 717-725.	1.4	5
17	A novel cross-correlation methodology for assessing biophysical responses associated with pain. <i>Journal of Pain Research</i> , 2018, Volume 11, 2207-2219.	0.8	7
18	Peripherally Inserted Central Catheters (PICCs), the Leading Cause of Central Venous Catheter Associated Thrombosis in Children. <i>Blood</i> , 2018, 132, 139-139.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1134-1141.	2.0	7
20	Individuals with sickle cell disease have a significantly greater vasoconstriction response to thermal pain than controls and have significant vasoconstriction in response to anticipation of pain. <i>American Journal of Hematology</i> , 2017, 92, 1137-1145.	2.0	30
21	Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL investigator meeting. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 349-354.	0.3	4
22	Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. <i>Cancer</i> , 2016, 122, 1928-1936.	2.0	90
23	Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progesterin response. <i>Gynecologic Oncology</i> , 2016, 143, 650-654.	0.6	12
24	The Effect of Patient and Contextual Characteristics on Racial/Ethnic Disparity in Breast Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1064-1072.	1.1	20
25	Validation of self-reported comorbidity status of breast cancer patients with medical records: the California Breast Cancer Survivorship Consortium (CBCSC). <i>Cancer Causes and Control</i> , 2016, 27, 391-401.	0.8	13
26	A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. <i>Clinical Cancer Research</i> , 2016, 22, 4014-4022.	3.2	56
27	Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. <i>Neuro-Oncology</i> , 2016, 18, 126-131.	0.6	69
28	Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. <i>Blood</i> , 2016, 128, 2781-2781.	0.6	5
29	Escalation of Oncologic Services at the End of Life Among Patients With Gynecologic Cancer at an Urban, Public Hospital. <i>Journal of Oncology Practice</i> , 2015, 11, e163-e169.	2.5	16
30	Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. <i>Journal of Community Health</i> , 2015, 40, 1287-1299.	1.9	53
31	Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 361-368.	1.1	62
32	Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1282-1290.	1.1	29
33	Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas. <i>Clinical Cancer Research</i> , 2015, 21, 1457-1465.	3.2	92
34	Thromboelastography to Detect Hypercoagulability in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1118-1118.	0.6	6
35	Comparison of Vincristine Pharmacokinetics (PK) in Adolescent/Young Adult (AYA) Versus Younger Patients Defined By Tanner Stage during Treatment for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2015, 126, 3725-3725.	0.6	2
36	MYCN-Dependent Expression of Sulfatase-2 Regulates Neuroblastoma Cell Survival. <i>Cancer Research</i> , 2014, 74, 5999-6009.	0.4	9

#	ARTICLE	IF	CITATIONS
37	Molecular and Clinical Diagnosis of Group A Streptococcal Pharyngitis in Children. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3884-3889.	1.8	30
38	Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2014, 124, 3932-3938.	0.6	78
39	Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-L). <i>Blood</i> , 2014, 124, 795-795.	0.6	19
40	Comparison of Taqman low density array (TLDA) five-gene assay for tumor cells in bone marrow and blood with histologic bone marrow examination and imaging for disease assessment and outcome in patients with recurrent/refractory neuroblastoma (NBL): A new approaches to neuroblastoma therapy (NANT) study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10039-10039.	0.8	0
41	Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation (AuHCT) in pediatric patients with malignant brain tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2049-2049.	0.8	0
42	A wide-spectrum paired comparison of the properties of the Rolling 6 and 3+3 Phase I study designs. <i>Contemporary Clinical Trials</i> , 2011, 32, 694-703.	0.8	12
43	Commentary on paper, "cancer survival analysis"™. <i>Surgical Oncology</i> , 2010, 19, 59-60.	0.8	2
44	An adjustment for patient heterogeneity in the design of two-stage phase II trials. <i>Statistics in Medicine</i> , 2009, 28, 2566-2579.	0.8	14
45	Cure model analysis in cancer: an application to data from the Children's Cancer Group. <i>Statistics in Medicine</i> , 2002, 21, 293-312.	0.8	110
46	Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. <i>Medical and Pediatric Oncology</i> , 2001, 37, 432-441.	1.0	40
47	A strategic view of randomized trial design in low-incidence paediatric cancer. , 1999, 18, 1183-1197.		17
48	Use of unequal allocation in survival trials. <i>Statistics in Medicine</i> , 1987, 6, 119-125.	0.8	22